Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
06 2022
Historique:
received: 24 11 2021
accepted: 06 05 2022
revised: 29 06 2022
pubmed: 17 6 2022
medline: 2 7 2022
entrez: 16 6 2022
Statut: epublish

Résumé

Both SIV and SHIV are powerful tools for evaluating antibody-mediated prevention and treatment of HIV-1. However, owing to a lack of rhesus-derived SIV broadly neutralizing antibodies (bnAbs), testing of bnAbs for HIV-1 prevention or treatment has thus far been performed exclusively in the SHIV NHP model using bnAbs from HIV-1-infected individuals. Here we describe the isolation and characterization of multiple rhesus-derived SIV bnAbs capable of neutralizing most isolates of SIV. Eight antibodies belonging to two clonal families, ITS102 and ITS103, which target unique epitopes in the CD4 binding site (CD4bs) region, were found to be broadly neutralizing and together neutralized all SIV strains tested. A rare feature of these bnAbs and two additional antibody families, ITS92 and ITS101, which mediate strain-specific neutralizing activity against SIV from sooty mangabeys (SIVsm), was their ability to achieve near complete (i.e. 100%) neutralization of moderately and highly neutralization-resistant SIV. Overall, these newly identified SIV bnAbs highlight the potential for evaluating HIV-1 prophylactic and therapeutic interventions using fully simian, rhesus-derived bnAbs in the SIV NHP model, thereby circumventing issues related to rapid antibody clearance of human-derived antibodies, Fc mismatch and limited genetic diversity of SHIV compared to SIV.

Identifiants

pubmed: 35709309
doi: 10.1371/journal.ppat.1010574
pii: PPATHOGENS-D-21-02365
pmc: PMC9242510
doi:

Substances chimiques

Antibodies, Neutralizing 0
Broadly Neutralizing Antibodies 0
HIV Antibodies 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010574

Subventions

Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201800004C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI112456
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Immunity. 2012 Sep 21;37(3):412-25
pubmed: 22999947
PLoS Pathog. 2018 Dec 5;14(12):e1007395
pubmed: 30517201
AIDS Res Hum Retroviruses. 2011 May;27(5):487-500
pubmed: 20854170
PLoS Pathog. 2015 Aug 12;11(8):e1005110
pubmed: 26267277
J Virol. 2016 Nov 14;90(23):10574-10586
pubmed: 27654288
J Virol. 1997 Oct;71(10):7895-902
pubmed: 9311879
J Virol. 1993 Jul;67(7):4104-13
pubmed: 8510218
J Virol. 2013 May;87(10):5477-92
pubmed: 23468494
J Virol. 2017 Sep 27;91(20):
pubmed: 28768869
Cell. 2016 Sep 8;166(6):1471-1484.e18
pubmed: 27610571
Hum Vaccin. 2009 Mar;5(3):141-50
pubmed: 18690014
Science. 2012 Mar 9;335(6073):1188-93
pubmed: 22403383
J Virol. 2007 Aug;81(15):7913-23
pubmed: 17507488
Nucleic Acids Res. 2015 Jan;43(Database issue):D413-22
pubmed: 25378316
Front Immunol. 2016 Jan 28;7:12
pubmed: 26858716
Front Immunol. 2017 Oct 27;8:1407
pubmed: 29163486
Retrovirology. 2018 Oct 16;15(1):70
pubmed: 30326938
J Virol. 2012 Dec;86(24):13217-31
pubmed: 23055550
J Virol. 2009 Jul;83(14):7337-48
pubmed: 19439467
J Virol. 2011 May;85(10):4828-40
pubmed: 21389135
J Infect Dis. 2021 Feb 13;223(3):370-380
pubmed: 32604408
Sci Transl Med. 2019 Oct 30;11(516):
pubmed: 31666399
Sci Transl Med. 2017 Sep 6;9(406):
pubmed: 28878010
J Virol. 2005 Oct;79(19):12455-63
pubmed: 16160173
Nature. 2012 Nov 15;491(7424):406-12
pubmed: 23151583
Front Immunol. 2016 Sep 21;7:372
pubmed: 27708645
Immunity. 2019 Oct 15;51(4):724-734.e4
pubmed: 31586542
AIDS Res Hum Retroviruses. 1990 Nov;6(11):1221-31
pubmed: 2078405
Nat Protoc. 2013 Oct;8(10):1907-15
pubmed: 24030440
Cell Host Microbe. 2014 Sep 10;16(3):304-13
pubmed: 25211073
Science. 2011 Sep 16;333(6049):1593-602
pubmed: 21835983
J Virol. 2016 Dec 16;91(1):
pubmed: 27795431
Cell. 2015 Jun 4;161(6):1280-92
pubmed: 26004070
J Virol. 2011 Jun;85(12):5764-72
pubmed: 21490100
PLoS One. 2021 Mar 22;16(3):e0248973
pubmed: 33752225
Nat Protoc. 2016 Oct;11(10):1908-1923
pubmed: 27658009
AIDS Res Hum Retroviruses. 1992 Mar;8(3):367-72
pubmed: 1571196
AIDS Res Hum Retroviruses. 2017 Aug;33(8):869-879
pubmed: 28075174
Immunity. 2019 Feb 19;50(2):520-532.e3
pubmed: 30709739
PLoS Pathog. 2016 Apr 11;12(4):e1005537
pubmed: 27064278
J Virol. 2014 Nov;88(21):12669-82
pubmed: 25142607
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
J Virol. 2010 Feb;84(3):1439-52
pubmed: 19939925
PLoS One. 2015 Mar 25;10(3):e0120451
pubmed: 25807114
AIDS. 2009 Nov 27;23(18):2405-14
pubmed: 19770692
Immunity. 2016 Nov 15;45(5):1108-1121
pubmed: 27851912
Retrovirology. 2018 Sep 5;15(1):61
pubmed: 30185183
PLoS Pathog. 2010 Aug 05;6(8):e1001028
pubmed: 20700449
J Virol. 2015 Aug;89(16):8130-51
pubmed: 26018167
J Virol. 2016 Apr 29;90(10):4966-4980
pubmed: 26937037
PLoS Comput Biol. 2019 Jun 6;15(6):e1007056
pubmed: 31170145
Structure. 2019 Jan 2;27(1):196-206.e6
pubmed: 30471922
Nat Commun. 2016 Dec 20;7:13642
pubmed: 27995928
AIDS. 2014 Jan 14;28(2):163-9
pubmed: 24361678
Immunity. 2018 May 15;48(5):855-871
pubmed: 29768174
J Virol. 2015 Dec 30;90(6):2740-55
pubmed: 26719262
J Virol. 2011 Oct;85(19):10389-98
pubmed: 21775457
Immunity. 2013 Aug 22;39(2):245-58
pubmed: 23911655
Nature. 2016 May 5;533(7601):105-109
pubmed: 27120156
Science. 2010 Aug 13;329(5993):811-7
pubmed: 20616231
J Virol. 2009 Mar;83(6):2686-96
pubmed: 19129440
Cell. 2019 Jul 25;178(3):567-584.e19
pubmed: 31348886
Nature. 2011 Sep 22;477(7365):466-70
pubmed: 21849977
J Virol. 2010 Feb;84(3):1631-6
pubmed: 19923174
Nat Immunol. 2018 Nov;19(11):1179-1188
pubmed: 30333615
Sci Transl Med. 2017 Sep 20;9(408):
pubmed: 28931655
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Immunol Rev. 2013 Jul;254(1):225-44
pubmed: 23772623
Curr Protoc Immunol. 2005 Jan;Chapter 12:Unit 12.11
pubmed: 18432938
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701

Auteurs

Hugh C Welles (HC)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Hannah A D King (HAD)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.

Leonard Nettey (L)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Nicole Cavett (N)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Jason Gorman (J)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Tongqing Zhou (T)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Yaroslav Tsybovsky (Y)

Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.

Renguang Du (R)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Kaimei Song (K)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Richard Nguyen (R)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

David Ambrozak (D)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Amy Ransier (A)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Chaim A Schramm (CA)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Nicole A Doria-Rose (NA)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Adrienne E Swanstrom (AE)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.

James A Hoxie (JA)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Celia LaBranche (C)

Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.

David C Montefiori (DC)

Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.

Daniel C Douek (DC)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Peter D Kwong (PD)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

John R Mascola (JR)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Mario Roederer (M)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Rosemarie D Mason (RD)

Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH